Literature DB >> 14755733

SCA17 homozygote showing Huntington's disease-like phenotype.

Yasuko Toyoshima1, Mitsunori Yamada, Osamu Onodera, Mitsuteru Shimohata, Chikanori Inenaga, Nobuya Fujita, Masahiro Morita, Shoji Tsuji, Hitoshi Takahashi.   

Abstract

We report a homozygous case of spinocerebellar ataxia type 17 with 48 glutamines. The age of the patient at disease onset was not lower than those of heterozygotes with the same CAG-repeat sizes, but the clinical manifestations were rapidly progressive dementia and chorea. Neuronal loss was relatively restricted and most prominent in the Purkinje cell layer and striatum; however, intranuclear neuronal polyglutamine accumulation was widespread, with a high frequency in the cerebral cortex and striatum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755733     DOI: 10.1002/ana.10824

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  Magnetic resonance imaging in spinocerebellar ataxias.

Authors:  Susanne Döhlinger; Till-Karsten Hauser; Johannes Borkert; Andreas R Luft; Jörg B Schulz
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

2.  CAG repeats determine brain atrophy in spinocerebellar ataxia 17: a VBM study.

Authors:  Kathrin Reetz; Alexandra Kleiman; Christine Klein; Rebekka Lencer; Christine Zuehlke; Kathrin Brockmann; Arndt Rolfs; Ferdinand Binkofski
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

Review 3.  Genetically modified rodent models of SCA17.

Authors:  Yiting Cui; Su Yang; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci Res       Date:  2016-11-18       Impact factor: 4.164

4.  Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.

Authors:  Shanshan Huang; Joseph J Ling; Su Yang; Xiao-Jiang Li; Shihua Li
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

5.  Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Authors:  Yang Yang; Su Yang; Jifeng Guo; Yiting Cui; Beisha Tang; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci       Date:  2017-08-18       Impact factor: 6.167

6.  Large Polyglutamine Repeats Cause Muscle Degeneration in SCA17 Mice.

Authors:  Shanshan Huang; Su Yang; Jifeng Guo; Sen Yan; Marta A Gaertig; Shihua Li; Xiao-Jiang Li
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

7.  Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17.

Authors:  Kathrin Reetz; Rebekka Lencer; Johannes M Hagenah; Christian Gaser; Vera Tadic; Uwe Walter; Alexander Wolters; Susanne Steinlechner; Christine Zühlke; Katja Brockmann; Christine Klein; Arndt Rolfs; Ferdinand Binkofski
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

8.  Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice.

Authors:  Su Yang; Shanshan Huang; Marta A Gaertig; Xiao-Jiang Li; Shihua Li
Journal:  Neuron       Date:  2014-01-22       Impact factor: 17.173

9.  From normal gait to loss of ambulation in 6 months: a novel presentation of SCA17.

Authors:  R Mehanna; I Itin
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

Review 10.  Spinocerebellar ataxia type 17 is caused by mutations in the TATA-box binding protein.

Authors:  Christine Zühlke; Katrin Bürk
Journal:  Cerebellum       Date:  2007-01-19       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.